Biosimilar Medicines in Clinical Practice
Important Role for Hospital Pharmacists?

Satellite Symposium

EAHP Congress, Cannes

22 March 2017

patients • quality • value • sustainability • partnership

Biosimilar Medicines Group Membership

COMPANIES

Apobiologix | Boehringer Ingelheim | cinfa | EGIS | Gedeon Richter
Merck | Mylan | polpharma | SANDOZ | Samsung Bioepis
STADA | TEVA

ASSOCIATIONS

apogen | BOGIN | British Biosimilars Association | ČAFF | Fo Medicin
Rinnakkaislääkkeet | FGL | GEMME Biosimilaires | HEA | IEIS
igl | GENAS | intergenerika | iBG | biosimilars

26 EU approved biosimilar medicines



Adapted from Richardson P (2017) – Presented at EDQM Biosimilars: Satellite Session 08/02/17

Need for education & information on biosimilars?



Source: Beck M. et al. (2016) mAbs DOI: 10.1080/19420862.2016.1267087

Need for education & information on biosimilars?



Source: Beck M. et al. (2016) mAbs DOI: 10.1080/19420862.2016.1267087

Need for education & information on biosimilars?



Source: Beck M. et al. (2016) mAbs DOI: 10.1080/19420862.2016.1267087

What are we talking about?

Switching

Decision by **treating physician** to exchange one medicine for another medicines with the same therapeutic intent

Interchangeability

The medical practice of changing one medicine for another that is expected to achieve the same clinical effect in a given clinical setting and in any patient **on the initiative, or with the agreement of the prescriber**

Substitution

Practice of dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level **without consulting the prescriber**

Source: EC Consensus Document – What you need to know on Biosimilar Medicinal Products (2016)

Agenda

BIOSIMILAR MEDICINES IN CLINICAL PRACTICE

Important role for hospital pharmacists

AGENDA

Time	Topic	Speaker
14:00 – 14:05	Introduction	Sue Naeyaert
14:05 – 14:30	Clinical experience with biosimilar medicines	Teun van Gelder
14:30 – 14:55	The role of regulators to increase knowledge and confidence in biosimilar medicines – Danish perspective	Benedicte Lunddahl
14:55 – 15:20	Considerations for hospital pharmacists when biosimilar medicines enter the hospital	Barbara Claus
15:20 – 15:30	Expert discussion	

Speakers

Teun van Gelder	Benedicte Lunddahl	Barbara Claus
		
Erasmus Medical Center the Netherlands	Danish Medicines Agency (DKMA) Denmark	Ghent University Hospital Belgium